‘CBOE Makes Third Attempt To List ARK 21Shares Bitcoin ETF’ – BlockWorks

https://blockworks.co/news/cboe-ark-21shares-bitcoin-etf The proposed ETF, a collaboration between Cathie Wood’s Ark Invest and crypto investment product firm 21Shares, aims to list and trade on the Cboe BZX

https://blockworks.co/news/cboe-ark-21shares-bitcoin-etf

The proposed ETF, a collaboration between Cathie Wood’s Ark Invest and crypto investment product firm 21Shares, aims to list and trade on the Cboe BZX exchange

Cboe Global Markets has made its third attempt to secure regulatory approval for a spot Bitcoin ETF from the US Securities and Exchange Commission (SEC). 

The ARK 21Shares Bitcoin ETF, if approved, would allow investors to gain exposure to Bitcoin without owning the digital currency directly.

The proposed ETF, a collaboration between Cathie Wood’s Ark Invest and crypto investment product firm 21Shares, aims to list and trade on the Cboe BZX exchange, Reuters reported on Tuesday. It marks the latest effort by Cboe, following two previous unsuccessful attempts to list and trade the same ETF. 

Cboe BZX Exchange is one of the largest US equities market operators on any given day, clocking $1.4 billion in 24-hour trade volume. It is owned and operated by Cboe Global Markets, which also owns the Chicago Board Options Exchange and other exchanges around the world.

The operator has made attempts to list and trade the ARK 21Shares Bitcoin ETF in the past, including in May 2022 and August 2021. They were both rejected on the grounds the product did little to prevent fraud, according to the SEC.

The regulator has historically been cautious about such proposals, citing concerns over potential market manipulation and the lack of transparency in the crypto market.

To date, the SEC has rejected more than a dozen other proposals for spot bitcoin ETFs over a number of years, including from prominent firms such as Grayscale, Fidelity, and NYDIG. 

Despite the regulator’s reservations, the increasing demand for bitcoin and other digital assets has fueled a renewed push for regulatory approval of crypto-based financial products.

That’s led to the creation of US-based bitcoin futures ETFs, most notably from issuers Proshares, Valkyrie and VanEck, which have been available for nearly two years.

But a spot bitcoin ETF remains elusive. Comparable products are available in developed markets outside the US, and the SEC has faced criticism for its intransigence, to the point where Grayscale is suing the agency.

Total
0
Shares
Related Posts
Read More

Eisai And Biogen Announced FDA Accepts Filing of LEQEMBI Supplemental Biologics License Application For IV Maintenance Dosing To Treat Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that the U.S.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc.

BIIB

Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO